A Phase 1/2 interventional study of Arikayce™ 560 mg and Placebo for 560 mg in Cystic Fibrosis, sponsored by Insmed Incorporated. Completed at 19 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2019-06-04.
Sponsored by Insmed Incorporated · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 236th largest by enrollment of the 517 interventional ones that give a count, is one of 38 that started in 2008, is one of 32 in phase 1/2, and was the 93rd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 38 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 8 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.
CF is a gentic disease resulting from mutations in a 230 kb gene on chromosome 7 known as the cystic fibrosis transmembrane conductance regulator (CFTR). Study subjects with CF manifest pathological changes in a variety or organs that express CFTR. The lungs are frequently affected, the sequelae being chronic infections and airway inflammation. The principal goal of both treatment of subjects with CF is to slow the chronic deterioration of lung function.
Study subjects will be randomized to receive either study drug or placebo (1.5% NaCl) by inhalation via a PARI eFlow nebulizer. Each subject will complete 28 days of daily dosing. All study patients will be followed for safety, pharmacokinetics, clinical and microbiologic activity for 56 days post completion of study treatment. For the two lower doses (70 mg and 140 mg): patients received drug for 28 days, followed by a 28 day safety evaluation. For 560 mg: patients received drug for 28 days, followed by a 56 day safety evaluation. The total study period will be up to 84 days, with screening visit occurring within the preceding 14 days prior to study day 1. Patients will be clinically evaluated during the first 48 hours post first study dose and weekly for the 28 day treatment period and during the follow up visits at study days 35, 42, 49, 56, 70 and 85 days to determine safety and tolerability, pharmacokinetics (PK) and clinical and microbiologic activity.
Clinical laboratory parameters, audiology testing, clinical adverse events and pulmonary function will be evaluated for all study subjects in order to determine the qualitative and quantitative safety and tolerability of Arikayce™ compared to placebo. Serum, urine and sputum specimens will be collected at periodic intervals to assess PK. Additionally, sputum samples will be collected to determine changes in bacterial density. Pulmonary function testing and CFQ-R measurements will be assessed at selected time points throughout the study. An exploratory evaluation of a Cystic Fibrosis Symptom Diary (CFSD) will also be implemented. Arikace™,Arikayce™, Liposomal Amikacin for Inhalation (LAI), and Amikacin Liposome Inhalation Suspension (ALIS) may be used interchangeably throughout this study and other studies evaluating amikacin liposomal inhalation suspension.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
Drug: Arikayce™ 560 mg
Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
Drug: Placebo for 560 mg
Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
Drug: Arikayce™ 70 mg
Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
Drug: Arikayce™ 140 mg
Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
Drug: Placebo for 70 mg / 140 mg
Arikayce™ at 560 mg Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Matching placebo Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Matching placebo Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Number of Participants With Treatment-Emergent Adverse Events
To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikayce™, liposomal amikacin for inhalation.
Time frame: 56 days
Pharmacokinetics of Arikayce™ in Serum
Measure PK parameter (Cmax) of Arikayce in serum
Time frame: Day 1, Day 14 and Day 28
Pharmacokinetics (PK) of Arikayce™ in Sputum
Measure PK parameters (sputum concentration) of Arikayce in sputum, pre- and post-dose
Time frame: Day 1 post-dose, Day 14 pre- and post-dose, Day 28 pre- and post-dose
Pharmacokinetics (PK) of Arikayce™ in Urine
Measure PK parameter (Ae0-24) of Arikayce in urine
Time frame: Day 1, Day 14 and Day 28
Pharmacokinetics (PK) of Arikayce™ in Serum
Measure PK parameter (AUC) of Arikayce in Serum
Time frame: Day 1, Day 14 and Day 28
Pulmonary Function: Pre-Dose FEV1 (%-Predicted)
Relative Change (%) from Baseline to Day 28, Day 56, Day 70, and Day 84 in Pulmonary Function
Time frame: Baseline, Day 28, Day 56, Day 70 and Day 84
Density of Pseudomonas Aeruginosa in Sputum
Change (log10 CFU) from Baseline by Study Day and Treatment Arm
Time frame: Day 7, Day 14, Day 21, Day 28 and Day 35
Duration of Systemic Anti-Pseudomonal Rescue Therapy
Time frame: Through study duration, approximately 84 days
CFQ-R Respiratory Scale (Relative Change % From Baseline)
Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.
Time frame: Day 15, Day 28 and Day 42
| Milestone | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Started | 15 | 7 | 7 | 5 | 7 |
| Completed | 12 | 7 | 6 | 5 | 6 |
| Not completed | 3 | 0 | 1 | 0 | 1 |
To evaluate the safety and tolerability of 28 days of daily dosing of nebulized Arikayce™, liposomal amikacin for inhalation.
| Participants | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Patients with AEs | 14 | 7 | 7 | 4 | 6 |
| Patients with Treatment Related AEs | 7 | 2 | 2 | 2 | 2 |
| Deaths | 0 | 0 | 0 | 0 | 0 |
| Patients with Serious AEs | 5 | 2 | 0 | 1 | 1 |
| Patients Permanently Discontinuing due to AEs | 4 | 0 | 0 | 0 | 0 |
Measure PK parameter (Cmax) of Arikayce in serum
| mg/L | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Day 1 | 1.59 ± 0.973 | — | 0.216 ± 0.054 | 0.375 ± 0.167 | — |
| Day 14 | 2.17 ± 1.48 | — | 0.265 ± 0.060 | 0.447 ± 0.157 | — |
| Day 28 | 2.71 ± 1.75 | — | 0.293 ± 0.026 | 0.481 ± 0.213 | — |
Measure PK parameters (sputum concentration) of Arikayce in sputum, pre- and post-dose
| mcg/g | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce ™at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Day 1 1 hour post-dose | 4417 ± 74.5 | — | 1119 ± 64.5 | 1632 ± 36.9 | — |
| Day 14 pre-dose | 132 ± 205 | — | 150 ± 221 | 20.1 ± 43.8 | — |
| Day 14 1 hour post-dose | 2643 ± 101 | — | 1012 ± 119 | 1534 ± 63.3 | — |
| Day 28 pre-dose | 124 ± 114 | — | 49.7 ± 189 | 20.5 ± 57.0 | — |
| Day 28 1 hour post-dose | 2670 ± 66.2 | — | 753 ± 82.2 | 1468 ± 90.9 | — |
Measure PK parameter (Ae0-24) of Arikayce in urine
| mg | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce ™at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Day 1 | 25.9 ± 27.1 | — | 4.80 ± 1.43 | 15.2 ± 8.74 | — |
| Day 14 | 63.6 ± 29.1 | — | 7.76 ± 3.19 | 21.7 ± 12.4 | — |
| Day 28 | 62.9 ± 38.0 | — | 7.13 ± 4.31 | 17.7 ± 8.33 | — |
Measure PK parameter (AUC) of Arikayce in Serum
| mg*hr/L | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce ™at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Day 1 | 11.3 ± 5.81 | — | 1.06 ± 0.243 | 2.90 ± 1.08 | — |
| Day 14 | 15.0 ± 7.96 | — | 1.56 ± 0.553 | 4.32 ± 1.96 | — |
| Day 28 | 17.1 ± 7.58 | — | 1.59 ± 0.531 | 4.16 ± 1.56 | — |
Relative Change (%) from Baseline to Day 28, Day 56, Day 70, and Day 84 in Pulmonary Function
| Percent (%) | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Baseline | 68.800 ± 17.026 | 66.143 ± 12.020 | 59.286 ± 12.593 | 70.400 ± 10.090 | 69.286 ± 16.550 |
| Day 28 | -0.003 ± 0.124 | -0.001 ± 0.075 | 0.029 ± 0.124 | -0.029 ± 0.089 | -0.010 ± 0.060 |
| Day 56 | 0.029 ± 0.092 | -0.028 ± 0.129 | 0.024 ± 0.076 | -0.020 ± 0.087 | 0.011 ± 0.067 |
| Day 70 | 0.026 ± 0.107 | -0.043 ± 0.097 | — | — | — |
| Day 84 | 0.000 ± 0.078 | -0.067 ± 0.145 | — | — | — |
Change (log10 CFU) from Baseline by Study Day and Treatment Arm
| Log 10 CFU/g | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Day 7 | -1.605 ± 1.308 | 1.118 ± 2.214 | -1.093 ± 0.616 | -0.637 ± 0.711 | -0.254 ± 0.991 |
| Day 14 | -1.082 ± 1.354 | 1.098 ± 2.477 | -1.121 ± 1.404 | -0.175 ± 1.014 | -0.159 ± 0.499 |
| Day 21 | -0.750 ± 1.466 | -0.057 ± 0.600 | -1.560 ± 2.845 | -0.255 ± 1.977 | -0.337 ± 1.384 |
| Day 28 | -1.576 ± 1.979 | 0.836 ± 1.544 | -1.771 ± 1.741 | -0.381 ± 0.660 | -0.426 ± 0.435 |
| Day 35 | -1.963 ± 2.456 | 0.578 ± 0.539 | -0.675 ± 0.452 | 0.256 ± 1.058 | 0.028 ± 0.243 |
| days | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Duration of Systemic Anti-Pseudomonal Rescue Therapy | 22.800 ± 12.778 | 30.333 ± 15.044 | 17.500 ± 4.950 | 18.000 ± 0 | 30.500 ± 10.607 |
Quality of Life was measured by the absolute change from baseline in the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory scale. Disease specific instrument designed to measure impact on overall health, daily life, perceived well-being and symptoms in patients with a diagnosis of cystic fibrosis. Scores range from 0 to 100, with higher scores indicating better health. Scores for each Health Related Quality of Life (HRQoL) domain; after recoding, each item is summed to generate a domain score and standardized.
| Percent (%) | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce ™at 140 mg | Placebo at 70mg/140 mg |
|---|---|---|---|---|---|
| Day 15 | 0.385 ± 0.638 | -0.063 ± 0.135 | 0.075 ± 0.273 | 0.100 ± 0.173 | 0.042 ± 0.104 |
| Day 28 | 0.387 ± 0.683 | -0.054 ± 0.229 | 0.126 ± 0.255 | 0.228 ± 0.304 | -0.029 ± 0.233 |
| Day 42 | 0.094 ± 0.826 | -0.084 ± 0.258 | -0.012 ± 0.305 | 0.225 ± 0.215 | 0.006 ± 0.173 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arikayce™ at 560 mg | 0/15 (0%) | 5/15 (33.3%) | 14/15 (93.3%) |
| Placebo at 560 mg | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Arikayce™ at 70 mg | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Arikayce™ at 140 mg | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Placebo at 70 mg/140 mg | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Event | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70 mg/140 mg |
|---|---|---|---|---|---|
| Cystic Fibrosis ExacerbationRespiratory, thoracic and mediastinal disorders | 4/15 | 0/7 | 0/7 | 0/5 | 0/7 |
| Pulmonary exacerbationRespiratory, thoracic and mediastinal disorders | 2/15 | 1/7 | 0/7 | 1/5 | 0/7 |
| LOBE PNEUMONIAInfections and infestations | 0/15 | 0/7 | 0/7 | 0/5 | 1/7 |
| migraine headachesNervous system disorders | 0/15 | 1/7 | 0/7 | 0/5 | 0/7 |
| Elevated LFTsInvestigations | 0/15 | 1/7 | 0/7 | 0/5 | 0/7 |
| Event | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70 mg/140 mg |
|---|---|---|---|---|---|
| Lung disorderRespiratory, thoracic and mediastinal disorders | 7/15 | 1/7 | 2/7 | 1/5 | 3/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/15 | 3/7 | 1/7 | 0/5 | 1/7 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 3/15 | 3/7 | 0/7 | 0/5 | 0/7 |
| NauseaGastrointestinal disorders | 2/15 | 0/7 | 2/7 | 0/5 | 1/7 |
| FatigueGeneral disorders | 2/15 | 0/7 | 2/7 | 1/5 | 1/7 |
| SinusitisInfections and infestations | 2/15 | 1/7 | 0/7 | 0/5 | 2/7 |
| HemoptysisRespiratory, thoracic and mediastinal disorders | 1/15 | 1/7 | 2/7 | 1/5 | 1/7 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 3/15 | 2/7 | 2/7 | 1/5 | 1/7 |
| Sinus CongestionRespiratory, thoracic and mediastinal disorders | 1/15 | 2/7 | 0/7 | 1/5 | 1/7 |
| WheezingRespiratory, thoracic and mediastinal disorders | 3/15 | 1/7 | 2/7 | 0/5 | 0/7 |
| Age, Continuous(years) | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70 mg/140 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 31.5 ± 14.5 | 26.3 ± 6.7 | 33.1 ± 9.7 | 35.4 ± 6.0 | 24.4 ± 6.3 | 29.9 ± 12.6 |
| Sex: Female, Male(Participants) | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70 mg/140 mg | Total |
|---|---|---|---|---|---|---|
| Female | 5 | 3 | 6 | 1 | 5 | 20 |
| Male | 10 | 4 | 1 | 4 | 2 | 21 |
| Race/Ethnicity, Customized(Participants) | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70 mg/140 mg | Total |
|---|---|---|---|---|---|---|
| White | 14 | 6 | 7 | 5 | 6 | 38 |
| Black | 1 | 1 | 0 | 0 | 1 | 3 |
| Region of Enrollment(Participants) | Arikayce™ at 560 mg | Placebo at 560 mg | Arikayce™ at 70 mg | Arikayce™ at 140 mg | Placebo at 70 mg/140 mg | Total |
|---|---|---|---|---|---|---|
| United States | 15 | 7 | 7 | 5 | 7 | 41 |
The record gives a start of Jan 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 10 years after primary completion. A results delay was requested in Sep 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amikacin